임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
기업
60건 표시 (상위 60건)
- 3상모집 예정· Acute Coronary Syndrome (ACS)Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
리드: 노바티스
- 3상모집 예정· Chronic Pruritus of Unknown OriginA Study to Evaluate Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)
리드: 노바티스
- 3상모집 중· Hidradenitis SuppurativaAn Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
리드: 노바티스
- 3상모집 중· Primary Myelofibrosis (PMF)A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
리드: 노바티스
- 3상모집 중· Progressive Supranuclear Palsy Richardson Syndrome (PSP-RS)A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy
리드: 노바티스
- 3상모집 중· Cardiovascular Disease and Lipoprotein(a)An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
리드: 노바티스
- 3상모집 중· Indication of the Parent ProtocolRemibrutinib Open Label Roll-over Post-trial Access Protocol
리드: 노바티스
- 3상모집 중· Huntington DiseaseA Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease
리드: 노바티스
- 3상모집 중· Primary Immunoglobulin A Nephropathy (IgAN)Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN
리드: 노바티스
- 3상모집 중· Secondary Progressive Multiple Sclerosis (SPMS)A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
리드: 노바티스
- 3상모집 중· Paroxysmal Nocturnal Hemoglobinuria (PNH)Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
리드: 노바티스
- 3상모집 중· Acute Coronary SyndromeEvaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
리드: 노바티스
- 3상모집 중· Kidney DiseasesOpen-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
리드: 노바티스
- 3상모집 중· Prostate CancerStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
리드: 노바티스
- 3상모집 중· Relapsing Multiple SclerosisEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
리드: 노바티스
- 3상모집 중· Somatostatin Receptor Positive (SSTR+)Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
리드: 노바티스
- 3상모집 중· Atherosclerotic Cardiovascular Disease (ASCVD)Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
리드: 노바티스
- 3상모집 중단 (진행 중)· Hidradenitis SuppurativaA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
리드: 노바티스
- 3상모집 중단 (진행 중)· Relapsing Multiple Sclerosis (RMS)Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
리드: 노바티스
- 3상모집 중· Familial Hypercholesterolemia - HomozygousStudy to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children With Homozygous Familial Hypercholesterolemia
리드: 노바티스
- 3상모집 중· Generalized Myasthenia GravisA Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
리드: 노바티스
- 3상모집 중단 (진행 중)· Hidradenitis SuppurativaA Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
리드: 노바티스
- 3상모집 중· Familial Hypercholesterolemia - HeterozygousStudy to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia
리드: 노바티스
- 3상모집 중· Prostate Cancer MetastaticStandard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
협력: 노바티스
- 3상모집 중· Hematologic MalignancyAn Extension Study for Patients Previously Enrolled in Studies With Pelabresib
리드: 노바티스
- 3상모집 중· Generalized Myasthenia GravisA Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
리드: 노바티스
- 3상모집 중단 (진행 중)· Polymyalgia RheumaticaOpen-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR)
리드: 노바티스
- 3상모집 중· Prostate Cancer MetastaticA Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer
협력: 노바티스
- 3상모집 중· Systemic Lupus ErythematosusPhase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
리드: 노바티스
- 3상모집 중· Atypical Hemolytic Uremic SyndromeEvaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS
리드: 노바티스
- 3상모집 중· Oligometastatic Prostate Cancer (OMPC)An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
리드: 노바티스
- 3상모집 중· Atypical Hemolytic Uremic SyndromeEfficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
리드: 노바티스
- 3상모집 중단 (진행 중)· Chronic Inducible UrticariaA Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines
리드: 노바티스
- 3상모집 중· Sickle Cell Anemia in ChildrenPromoting Utilization and Safety of Hydroxyurea Using Precision in Africa
협력: 노바티스
- 3상모집 중단 (진행 중)· Follicular Lymphoma (FL)A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma
리드: 노바티스
- 3상모집 중단 (진행 중)· Hyperlipoproteinemia (a)An Open Label Extension (OLE) Study to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
리드: 노바티스
- 3상모집 중· Chronic Spontaneous Urticaria24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
리드: 노바티스
- 3상모집 중단 (진행 중)· Systemic Lupus ErythematosusPhase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)
리드: 노바티스
- 3상모집 중단 (진행 중)· Primary Prevention of Atherosclerotic Cardiovascular DiseaseA Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
리드: 노바티스
- 3상모집 중단 (진행 중)· Systemic Lupus ErythematosusPhase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
리드: 노바티스
- 3상모집 중· Heterozygous or Homozygous Familial HypercholesterolemiaLong-term Safety and Tolerability of Inclisiran in Participants With HeFH or HoFH Who Have Completed the Pediatric ORION-16, ORION-13, ORION-20, or ORION-19 Studies
리드: 노바티스
- 3상모집 중단 (진행 중)· Primary Immune Thrombocytopenia (ITP)Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
리드: 노바티스
- 3상모집 중단 (진행 중)· Primary Immune ThrombocytopeniaA Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids
리드: 노바티스
- 3상모집 중단 (진행 중)· Warm Autoimmune Hemolytic Anemia (wAIHA)A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia
리드: 노바티스
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.